全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Characterization of Bleeding and Laboratory Phenotype in Hemophilia A Carriers: A Cross-Sectional Study in Benin

DOI: 10.4236/ojbd.2023.134017, PP. 148-159

Keywords: Carrriers of Hemophilia A, Bleeding Symptoms, APTT, Factor VIII, FVIII:C/FvW:Ag ratio

Full-Text   Cite this paper   Add to My Lib

Abstract:

Background: In Africa, hemophilia is underdiagnosed and carriers have long been considered free from bleeding symptoms. However, recent research has begun to reveal hemostatic abnormalities and bleeding manifestations in carriers of hemophilia A, particularly due to excessive inactivation of normal X chromosomes. Objective: To describe the bleeding symptoms and hemostatic abnormalities in carriers of hemophilia A (HA) in Benin. Methods: This study was conducted as a prospective cross-sectional investigation between April 2021 to March 2022. The study population consisted of identified through pedigrees of persons with hemophilia A being treated in various hospitals in Benin. Data were collected through interviews conducted by trained physician and each carrier underwent a biological workup. Results: A total of 71 hemophilia A carriers were included and 38 of whom were obligatory carriers. Thirty-one carriers (43.7%) reported abnormal bleeding symptoms. Menorrhagia has (71%) being the most important manifestation, followed by bleeding during or after childbirth (45.2%). Among the 71 carriers, 45 were of reproductive age. Of whom 22 (48.8%) had a Higham score exceeding 100. Activated partial thromboplastin time was prolonged in 7 carriers (9.9%). The mean activity factor VIII:C (FVIII:C) levels were 68.8 ± 34.9 IU/dL. The average FVIII:C level in obligatory carriers was 56.9% and among potential carriers, the average FVIII:C level was higher at 80.4%. However twelve female carriers (16.9%) had FVIII:C levels < 40%. The FVIII:C/FvWAg ratio was below 0.7 in 73.2% of female drivers. Obligatory carriers (p = 0.00003) and FVIII;

References

[1]  Jayandharan, G., Srivastava, A. and Srivastava, A. (2012) Role of Molecular Genetics in Hemophilia: From Diagnosis to Therapy. Seminars in Thrombosis and Hemostasis, 38, 64-78.
https://doi.org/10.1055/s-0031-1300953
[2]  Radic, C.P., Rossetti, L.C., Abelleyro, M.M., Tetzlaff, T., Candela, M., Neme, D., et al. (2015) Phenotype—Genotype Correlations in Hemophilia A Carriers Are Consistent with the Binary Role of the Phase between F8 and X-Chromosome Inactivation. Journal of Thrombosis and Haemostasis, 13, 530-539.
https://doi.org/10.1111/jth.12854
[3]  Iorio, A., Stonebraker, J.S., Chambost, H., Makris, M., Coffin, D., Herr, C., et al. (2019) Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males: A Meta-Analytic Approach Using National Registries. Annals of Internal Medicine, 171, 540-546.
https://doi.org/10.7326/M19-1208
[4]  Stonebraker, J.S., Bolton-Maggs, P.H., Soucie, J.M., Walker, I. and Brooker, M. (2010) A Study of Variations in the Reported Haemophilia a Prevalence around the World. Haemophilia, 16, 20-32.
https://doi.org/10.1111/j.1365-2516.2009.02127.x
[5]  Hermans, C. and Kulkarni, R. (2018) Women with Bleeding Disorders. Haemophilia, 24, 29-36.
https://doi.org/10.1111/hae.13502
[6]  Hirayama, A.B., Silva, A.K.C.D., Rocha, J.S. and Roberti, M.D.R.F. (2019) Prevalence of Symptoms in Hemophilia Carriers in Comparison with the General Population: A Systematic Review. Hematology, Transfusion and Cell Therapy, 41, 349-355.
https://doi.org/10.1016/j.htct.2019.02.006
[7]  Sauguet, P., Aguilar-Martinez, P., Boulot, P., Escudié, J.B., Schved, J.F. and Biron-Andréani, C. (2015) Carriers of Haemophilia: Experience of a French University Hospital. Journal de Gynécologie Obstétrique et Biologie de la Reproduction, 44, 565-576.
https://doi.org/10.1016/j.jgyn.2014.08.009
[8]  Plug, I., Mauser-Bunschoten, E.P., Bröcker-Vriends, A.H., van Amstel, H.K., van der Bom, J.G., van Diemen-Homan, J.E., et al. (2006) Bleeding in Carriers of Hemophilia. Blood, 108, 52-56.
https://doi.org/10.1182/blood-2005-09-3879
[9]  Seck, M., Faye, B.F., Sall, A., Sy, D., Touré, S.A., Dieng, N., et al. (2017) Bleeding Risk Assessment in Hemophilia A Carriers from Dakar, Senegal. Blood Coagulation & Fibrinolysis, 28, 642-645.
https://doi.org/10.1097/MBC.0000000000000653
[10]  Lambert, C., Meité, N.D., Sanogo, I., Lobet, S., Adjambri, E., Eeckhoudt, S., et al. (2019) Hemophilia Carrier’s Awareness, Diagnosis, and Management in Emerging Countries: A Cross-Sectional Study in Côte d’Ivoire (Ivory Coast). Orphanet Journal of Rare Diseases, 14, Article No. 26.
https://doi.org/10.1186/s13023-019-1005-9
[11]  Street, A.M., Ljung, R. and Lavery, S.A. (2008) Management of Carriers and Babies with Haemophilia. Haemophilia, 14, 181-187.
https://doi.org/10.1111/j.1365-2516.2008.01721.x
[12]  Diop, S., Haffar, A., Mahlangu, J., Chami, I., Kitchen, S. and Pierce, G. (2019) Improving Access to Hemophilia Care in Sub-Saharan Africa by Capacity Building. Blood Advances, 3, 1-4.
https://doi.org/10.1182/bloodadvances.2019GS121537
[13]  Ljung, R. and Tedgård, U. (2003) Genetic Counseling of Hemophilia Carriers. Seminars in Thrombosis and Hemostasis, 29, 31-36.
https://doi.org/10.1055/s-2003-37937
[14]  Mbanya, D.N., Diop, S., Ndoumba Mintya, A.N. and El Kiaby, M. (2021) Hemophilia Care in Africa: Status and Challenges. Transfusion Clinique et Biologique, 28, 158-162.
https://doi.org/10.1016/j.tracli.2021.01.008
[15]  Yoo, K.Y., Jung, S.Y., Choi, J.Y., Park, H.R. and Park, Y.S. (2022) Clinical Application of Factor VIII: C to VWF: Ag Ratio for the Screening of Haemophilia A Carriers. Journal of Clinical Medicine, 11, Article 1686.
https://doi.org/10.3390/jcm11061686
[16]  Naicker, T., Aldous, C. and Thejpal, R. (2016) Haemophilia: A Disease of Women as Well. South African Journal of Child Health, 10, 29-32.
https://doi.org/10.7196/SAJCH.2016.v10i1.961
[17]  Baglo-Agbodandé, T., Zohoun, A., Agbeille, F., Abdelbakhit, D., Houssou, B., Massi, R., et al. (2022) Seroprevalence of HIV, HBV and HCV Viral Markers in Hemophiliacs in Benin. Les cahiers du CBRST Médecine et santé publique, 21, 176-189.
[18]  Bernard, W., Lambert, C., Henrard, S. and Hermans, C. (2018) Screening of Haemophilia Carriers in Moderate and Severe Haemophilia A and B: Prevalence and Determinants. Haemophilia, 24, e142-e144.
https://doi.org/10.1111/hae.13468
[19]  Van Galen, K.P.M., d’Oiron, R., James, P., Abdul-Kadir, R., Kouides, P.A., Kulkarni Rand., et al. (2021) A New Hemophilia Carrier Nomenclature to Define Hemophilia in Women and Girls: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 19, 1883-1887.
https://doi.org/10.1111/jth.15397
[20]  Miesbach, W., Alesci, S., Geisen, C. and Oldenburg, J. (2011) Association between Phenotype and Genotype in Carriers of Haemophilia A. Haemophilia, 17, 246-251.
https://doi.org/10.1111/j.1365-2516.2010.02426.x
[21]  Shoukat, H.M.H., Ghous, G., Tarar, Z.I., Shoukat, M.M. and Ajmal, N. (2020) Skewed Inactivation of X Chromosome: A Cause of Hemophilia Manifestation in Carrier Females. Cureus, 12, e11216.
https://doi.org/10.7759/cureus.11216
[22]  Pavlova, A., Brondke, H., Müsebeck, J., Pollmann, H., Srivastava, A. and Oldenburg, J. (2009) Molecular Mechanisms Underlying Hemophilia A Phenotype in Seven Females. Journal of Thrombosis and Haemostasis, 7, 976-982.
https://doi.org/10.1111/j.1538-7836.2009.03346.x

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133